CryoHoldco is a stem cell bank holding company that is the market leader in Latin America and one of the top 10 largest cord blood banks in the world. By the end of 2020, CryoHoldco will be seven times larger than any other stem cell bank in Latin America and will have 275,000 stem cell units in storage.
Pivotal Trends Impacting the Global Cord Blood Industry in 2020
The cord blood industry came into existence in the early 1990’s with the formation of several cord blood banks in the U.S. and worldwide. It has also been almost 40 years since it was first proposed that stem and progenitor cells were present in human cord blood. [Read more…]
Cord Blood Industry Consolidation Escalates as 2020 Approaches
The global cord blood industry experienced strong growth from the early 1990’s through the mid 2000’s, during which time more than 450 cord blood banking companies emerged worldwide. Approximately half of those companies owned their own labs, while the others were marketing entities or sub-contractors of storage space.
Starting about ten years ago, the market suddenly changed course. It entered a period of aggressive consolidation.
Over the past decade, the cord blood industry has witnessed substantial consolidation, particularly within the United States, Europe, and Latin America.
With CBR’s recent acquisition of Natera’s Evercord™ Cord Blood Business on September 13, 2019, the trend of cord blood industry consolidation continues. [Read more…]
An Expert’s Perspective on Accelerated Pathways for Cell Therapy Approvals
Over the past few years, the regulatory landscape for cell therapy development has grown increasingly complex. There are now accelerated pathways for advanced therapy medicinal products (ATMPs) in several countries worldwide, including the U.S., Japan, and South Korea. While the possibility for accelerated commercialization has resulted from these changes, substantial complexity has also been introduced, making it a more elaborate process to move cell therapy products from “bench to bedside.”
In the interview with Yaron Ramati, Director of Regulatory Affairs at Pluristem Therapeutics, we get an expert’s perspective on how the regulatory environment has changed and new opportunities that exist for bringing cell therapy products through the clinical trial process and into the global marketplace. [Read more…]
Introducing the Dawn of MSCs with RoosterBio Founder, Jon Rowley
Founded by Dr. Jon Rowley, RoosterBio is a privately held stem cell tools and technology company focused on accelerating the development of a sustainable regenerative medicine industry. Its products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. I had the honor of interviewing Dr. Jon Rowley, who is now the CTO of RoosterBio.
In this interview, we explore RoosterBio’s recent product launches, collaborations, achievements and future trajectory. [Read more…]